Skip to main content
Clinical Trials/EUCTR2012-004074-25-DE
EUCTR2012-004074-25-DEActive, not recruitingPhase 1

Comparison of the efficacy and safety of two different starting dosages of prednisolone in early active rheumatoid arthritis: a randomized, placebo controlled trial - CORRA

Ruhr-Universität Bochum0 sites450 target enrollmentStarted: July 29, 2013Last updated:
Drugs

Trial Snapshot

Phase
Phase 1
Status
Active, not recruiting
Enrollment
450

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional clinical trial of medicinal product

Eligibility Criteria

Sex
All

Inclusion Criteria

  • Diagnosis of rheumatoid arthritis based on expert opinion according to the ACR/EULAR 2009 criteria (Hawker 2009), disease duration < 3 years, active disease: DAS 28 ESR (Prevoo et al 1995) > 4 plus = 3 swollen joints
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 225
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 225

Exclusion Criteria

  • Prior treatment with DMARDs (except for hydroxychloroquin or sulfasalazine or methotrexate during the last four weeks before screening)
  • Clinically relevant comorbidity:
  • concurrent liver disease (ALT > 2 times upper limit of normal),
  • active hepatitis B or C viral infection,
  • renal disease (creatinine clearance < 30 ml/minute),
  • clinically relevant haematological disease due to the
  • judgement of the rheumatologist,
  • uncontrolled diabetes mellitus,
  • relevant immunodeficiency incl. HIV-infection,
  • clinically significant pulmonary fibrosis,
  • presence or history of severe infections,
  • pregnancy or planned pregnancy,
  • non-compliance,
  • age < 18 years.

Investigators

Similar Trials